18-07-2025
Concord Biotech completes EU GMP inspection at Dholka API facility
By Aditya Bhagchandani Published on July 18, 2025, 13:10 IST
Shares of Concord Biotech may remain in focus after the company announced that it has successfully completed the European Union Good Manufacturing Practice (EU GMP) inspection at its Active Pharmaceutical Ingredient (API) manufacturing facility in Dholka, Gujarat.
In a regulatory filing on July 18, 2025, the company informed the exchanges that the inspection at the Dholka facility was conducted from July 14 to July 18, 2025. The audit was concluded without any critical observations, reflecting the company's adherence to global regulatory standards.
'This achievement underscores our unwavering commitment to upholding the highest standards of quality, safety, and regulatory compliance across all aspects of our operations. It reflects our dedication to excellence and our continued focus on meeting the rigorous requirements of global regulatory authorities,' the company said in the statement.
The EU GMP certification is considered a key milestone for pharmaceutical companies, enabling them to export APIs to regulated markets in Europe and beyond.
Hina Patel, Company Secretary and Compliance Officer of Concord Biotech, signed off the communication, which was addressed to both the National Stock Exchange of India and the BSE Limited.
Investors and market participants will watch the stock closely as the EU GMP certification strengthens Concord Biotech's position in international markets and reinforces confidence in its manufacturing quality.
Ahmedabad Plane Crash
Aditya Bhagchandani serves as the Senior Editor and Writer at Business Upturn, where he leads coverage across the Business, Finance, Corporate, and Stock Market segments. With a keen eye for detail and a commitment to journalistic integrity, he not only contributes insightful articles but also oversees editorial direction for the reporting team.
